PT Kalbe Farma Tbk. (KLBF) : Distribution Drives the Top Line, Margins Remain the Swing Factor


by Fadly Rafiudin (Equity Research Analyst)
20 November 2026

KLBF’s 9M26 revenue grew +11.5% YoY to IDR 29.0 tn (from IDR 26.0 tn in 9M25), running ahead of our previous FY26F forecast at 76.4% (9M25: 73.6% of FY25 revenue). 3Q26 revenue alone rose +6.6% YoY to IDR 9.5 tn (from IDR 8.9 tn in 3Q25; -3.1% QoQ), with Distribution & Logistics remaining the standout at +12.2% YoY to IDR 3.4 tn. GPM compressed to 37.6% in 9M26 (vs. 40.5% in 9M25), as gross profit rose only +3.6% YoY to IDR 10.9 tn on raw material costs and product mix. OPM eased to 12.1% (vs. 12.8% in 9M25) and NPM to 9.4% (vs. 10.1% in 9M25), with net profit of IDR 2.7 tn (+4.0% YoY), equating to 73.8% of our FY26F net profit, in line with our expectations. 3Q26 net profit rebounded +24.5% YoY to IDR 817 bn, as promotion spend fell -19.8% YoY to IDR 776 bn. We raise our FY26F revenue to IDR 39.1 tn (previously IDR 37.9 tn) and maintain our FY26F net profit at IDR 3.71 tn. We maintain our “Buy” rating on KLBF with an unchanged target price of IDR 1,100/share.


9M26 & 3Q26 Financial Performance

Double-digit growth sustained into 9M26. KLBF’s 9M26 revenue grew +11.5% YoY to IDR 29.0 tn (from IDR 26.0 tn in 9M25), outpacing the +7.2% YoY growth recorded in 9M25. 3Q26 revenue rose +6.6% YoY to IDR 9.5 tn (from IDR 8.9 tn in 3Q25) but eased -3.1% QoQ (from IDR 9.8 tn in 2Q26).


Distribution continues to lead the growth. In 9M26, Distribution & Logistics revenue rose +21.6% YoY to IDR 10.6 tn (from IDR 8.7 tn in 9M25), lifting its contribution to 36.5% of revenue (vs. 33.4% in 9M25). Prescription Pharmaceuticals rose +6.5% YoY to IDR 8.2 tn, Consumer Health +9.9% YoY to IDR 4.0 tn and Nutritionals +4.1% YoY to IDR 6.3 tn. In 3Q26, Distribution grew +12.2% YoY (-9.5% QoQ) to IDR 3.4 tn, Prescription +5.2% YoY (+6.9% QoQ) to IDR 2.9 tn and Consumer Health +8.0% YoY (-5.0% QoQ) to IDR 1.2 tn, while Nutritionals was flat (-0.5% YoY, -3.4% QoQ) at IDR 2.0 tn.


Margins remain under pressure from costs and mix. 9M26 GPM compressed to 37.6% (vs. 40.5% in 9M25), with gross profit up only +3.6% YoY to IDR 10.9 tn. In 3Q26, GPM was 37.8% (vs. 39.5% in 3Q25/36.8% in 2Q26), dragged by Prescription, whose GPM slid to 45.3% (vs. 50.0% in 3Q25) on USD-linked raw material costs and product mix. OPM eased to 12.1% in 9M26 (vs. 12.8% in 9M25) but improved to 11.3% in 3Q26 (vs. 9.2% in 3Q25), as promotion spend fell -19.8% YoY to IDR 776 bn.


Bottom line holds up and stays in line with our estimates. 9M26 net profit rose +4.0% YoY to IDR 2.7 tn (from IDR 2.6 tn in 9M25), equating to 73.8% of our FY26F net profit forecast, in line with our expectations, with NPM at 9.4% (vs. 10.1% in 9M25). 3Q26 net profit rose +24.5% YoY to IDR 817 bn (from IDR 656 bn in 3Q25) but eased -8.2% QoQ (from IDR 891 bn in 2Q26), with NPM at 8.6% (vs. 7.4% in 3Q25/9.1% in 2Q26).



Cost Risks Persist into 4Q26F

IDR depreciation remains an ongoing cost risk. The rupiah closed at IDR 18,268/USD on 16 November 2026, weaker by around 8% YoY (from ~IDR 16,700/USD in November 2025) and from ~IDR 17,850/USD at our 2Q26 update. This remains a key concern given the significant USD-denominated raw material base, already visible in the Prescription GPM decline to 45.3% in 3Q26 (vs. 50.0% in 3Q25), and particularly relevant for the Nutritionals segment.


Oil prices lift distribution costs. Brent rose +42% QoQ to around USD 104/barrel in 3Q26, and non- subsidized fuel prices (incl. Dexlite) were raised on 2 September. The impact so far shows up in distribution rather than gross margin: transportation and delivery expenses rose +43.2% YoY to IDR 242 bn in 3Q26 (2.5% of revenue vs. 1.9% in 3Q25), while manufacturing overhead was flat. Although Brent has eased to around USD 92/barrel, fuel prices have stayed at September levels through November, which should keep transportation costs at or above the 3Q26 run-rate.


We raise FY26F revenue, but keep net profit unchanged. We raise our FY26F revenue to IDR 39.1 tn (previously IDR 37.9 tn), as 9M26 revenue has already reached 76.4% of our previous forecast, above the typical 9M share of ~74% in 2023-2025, led by Distribution & Logistics (+21.6% YoY in 9M26), while 4Q revenue is seasonally higher than 3Q. We keep our FY26F net profit at IDR 3.71 tn, however, as most of the additional revenue comes from lower-margin Distribution, gross margin remains pressured by USD- denominated raw materials and distribution costs keep rising. 9M26 net profit of IDR 2.7 tn equals 73.8% of our forecast, in line with its historical 9M run-rate.


Maintain “Buy” Recommendation with Target Price of IDR 1,100

We maintain our “Buy” rating on KLBF with an unchanged target price of IDR 1,100/share (13.4x FY26F P/E), offering +42.9% upside. The stock trades at ~9.4x FY26F P/E, below the -1 standard deviation level (12.2x) of its 3-year historical range, while our target multiple remains well below the 3-year mean of 18.1x. KLBF’s multi-segment platform provides a natural hedge against segment-specific cyclicality, while Enseval, the largest healthcare distribution network, remains its competitive moat.


Risks: (1) prolonged rupiah weakness further compressing GPM on USD-denominated raw materials, (2) weaker household purchasing power weighing on Nutritionals and Consumer Health volumes, (3) pricing pressure on generic and JKN-tendered Prescription products and (4) higher fuel and logistics costs eroding Distribution margins.

 

 Download full Report HERE